http://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Tue, 22 May 2018 23:59:47 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - OptiBiotix Health inks US deal for cholesterol breakthrough ]]> http://www.proactiveinvestors.co.uk/companies/news/197423/optibiotix-health-inks-us-deal-for-cholesterol-breakthrough-197423.html OptiBiotix Health PLC (LON:OPTI) confirmed it has inked a deal with Seed Health, which will produce, promote, market and commercialise in the US products containing the former's cholesterol-lowering additive, LP-LDL.

Financial details of the non-exclusive agreement weren't disclosed. But, investors were told Seed has developed a product concept which combines multiple strains of different probiotics that have been selected because of strong clinical trial data. 

WATCH: OptiBiotix scoops award for Weight Management Ingredient of the Year

OptiBiotix's LP-LDL strain has published human data demonstrating significant statistical and clinical reductions in cholesterol and blood pressure.

Shared vision 

"We chose Seed due to our shared vision of commercialising products with strong scientific and clinical data, their innovative product concept, and their ability to access the large US consumer goods market," said chief executive Stephen O'Hara.  

"We are pleased that our strong science, successful human studies and international awards at major scientific conferences has attracted international interest in our products leading to continued regular deal flow as we build multiple revenue streams from partners across the world."

Optibiotix has developed a number of compounds that interact with the human microbiome to tackle obesity, high cholesterol, diabetes and skin complaints.

Complex interaction 

The microbiome is a complex interaction of bacteria that exists in the gut and on the skin and it's known fine tweaks to it can affect and improve health.

LP-LDL is one of a number of developments by CEO O'Hara and his team that tap into huge potential markets. 

America is one of the largest and fastest growing probiotic markets in the world, with supplement sales currently around US$2.1bn annually and the market expected to grow to US$3.3bn by 2021.

Partner Seed was co-founded and is led by Raja Dhir and Ara Katz to pioneer the application of microbiome science. 

In collaboration with leading scientists and a global network of partners and experts in biofermentation, stabilisation and testing, Seed reckons it has developed a new standard for a pipeline of effective, scientifically-validated probiotics that target the human microbiome. 

The shares, up 23% in the last month, advanced 2.4% early on to 74p, valuing the business at just shy of £60mln.

---- adds share price ----

 

]]>
Tue, 22 May 2018 07:48:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197423/optibiotix-health-inks-us-deal-for-cholesterol-breakthrough-197423.html
<![CDATA[RNS press release - LP-LDL agreement for USA ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180522070002_13649544/ Tue, 22 May 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180522070002_13649544/ <![CDATA[Media files - OptiBiotix scoops award for Weight Management Ingredient of the Year ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/9335/optibiotix-scoops-award-for-weight-management-ingredient-of-the-year-9335.html Mon, 21 May 2018 08:42:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/9335/optibiotix-scoops-award-for-weight-management-ingredient-of-the-year-9335.html <![CDATA[News - OptiBiotix SlimBiome wins award for Weight Management Ingredient of the Year ]]> http://www.proactiveinvestors.co.uk/companies/news/197254/optibiotix-slimbiome-wins-award-for-weight-management-ingredient-of-the-year-197254.html OptiBiotix Health plc (LON:OPTI) has announced that its weight management ingredient SlimBiome has won the award for Weight Management Ingredient of the Year at the Vitafoods European tradeshow in Geneva.

The AIM-listed firm said the award is given to the product identified by a panel of scientific, regulatory and industry experts demonstrating leading edge research and innovation in the weight management market.

READ: OptiBiotix to bring cholesterol reduction product to India with new agreement

OptiBiotix, which develops a range of compounds to tackle obesity, high cholesterol, diabetes and skin care, said the award for Weight Management Ingredient of the Year at Vitafoods is the second industry award for SlimBiome.

In November 2017 SlimBiome won the award for ‘Best Functional Ingredient for Health and Well Being’ at Food Matters.

Stephen O’Hara, CEO of OptiBiotix, said: “Having a product with a known mechanism of action, clinical and consumer studies showing its safety and effectiveness, and the support of leading international key opinion leaders, helps give confidence to consumers in their product choice.”

He added: “Hunger free dieting is now a consumer option and we hope that the increasing number of food applications containing SlimBiome will help bring the benefits of this exciting new technology to a wider international audience."

  

]]>
Fri, 18 May 2018 07:33:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197254/optibiotix-slimbiome-wins-award-for-weight-management-ingredient-of-the-year-197254.html
<![CDATA[RNS press release - SlimBiome® wins award at Vitafoods 2018 ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180518070005_13646132/ Fri, 18 May 2018 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180518070005_13646132/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180516164039_13644111/ Wed, 16 May 2018 16:40:39 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180516164039_13644111/ <![CDATA[News - OptiBiotix to bring cholesterol reduction product to India with new agreement ]]> http://www.proactiveinvestors.co.uk/companies/news/197069/optibiotix-to-bring-cholesterol-reduction-product-to-india-with-new-agreement-197069.html OptiBiotix Health PLC (LON:OPTI) has signed a five-year exclusive manufacturing and supply agreement for its cholesterol and blood pressure reducing strain in India.

The AIM-listed company, which develops a range of compounds to tackle obesity, high cholesterol, diabetes and skin care, said the agreement was with Akums Drugs and Pharmaceuticals Ltd, a leading contract manufacturer in India.

READ: OptiBiotix to present new products and research data at leading industry trade show next week

Under the terms of the agreement, Akums will manufacture and supply products containing OptiBiotix’s LPLDL strain throughout India to maximise financial return for both parties.

In return for exclusivity, the group said Akums would provide undisclosed and in-kind contributions and explore opportunities to utilise LPLDL with OptiBiotix therapeutics in India, including any required authority registrations.

Akums will also contribute to any required human studies for product marketing purposes or by the Food Safety Standards Authority of India (FSSAI) as part of product registration into food.

Optibiotix added that the agreement does not have any minimum sales orders and that it would update the market on sales in due course.

Akums is the largest contract manufacturing organisation in India, supplying more than 12% of all food and drug supplements consumed in the country, and has manufacturing partnerships with over 600 companies including Abbott (NYSE:ABT), Novartis, P&G (NYSE:PG), Sanofi and Sandoz, in the pharmaceutical and food supplement space.

Stephen O’Hara, OptiBiotix chief executive, said in a statement: "We are excited to announce this agreement with Akums which expands manufacturing and sales of LPLDL® into Asia. We chose Akums as they are the largest contract manufacturing company in India for both food supplements and pharmaceuticals and have extensive experience in manufacturing products for some of the biggest food and pharmaceutical companies in the world.

He added: "This agreement is a strategic step to add manufacturing to the supply chain in the Asian probiotic supplement and pharmaceutical market and extends the commercial reach of OptiBiotix's LPLDL® strain into Southern Asia. This allows OptiBiotix to offer multiple product solutions to consumer health and pharmaceutical companies within the region.

"This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, white label and own label branded consumer and pharmaceutical products, across multiple channels, with leading industry partners from around the world."

In a note to clients, analysts at City broker finnCap said the agreement was “further evidence of the foundations that OptiBiotix is building for its LP-LDL probiotic strain.”

They added: “This represents the ninth agreement for LP-LDL and continues to demonstrate the company’s ability to attract high calibre, global partners, eager to utilise the potential cardiovascular benefits inherent within LP-LDL.”

In late-morning trading, OptiBiotix shares were steady around 73.5p.

-- Adds broker comment and share price --

]]>
Wed, 16 May 2018 07:31:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197069/optibiotix-to-bring-cholesterol-reduction-product-to-india-with-new-agreement-197069.html
<![CDATA[RNS press release - Exclusive manufacturing and supply agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180516070003_13642559/ Wed, 16 May 2018 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180516070003_13642559/ <![CDATA[News - OptiBiotix to present new products and research data at leading industry trade show next week ]]> http://www.proactiveinvestors.co.uk/companies/news/196520/optibiotix-to-present-new-products-and-research-data-at-leading-industry-trade-show-next-week-196520.html OptiBiotix Health plc (LON:OPTI) is to show off a range of new SlimBiome products and the latest research data on its LPLDL heart health products at a prestigious industry conference in Switzerland next week.

The life sciences group has been developing a range of new product concepts which feature its SlimBiome weight loss ingredient, including natural fruit gummies, muesli pots, Nutri-Bites and flavours for new bars; all of which it will showcase at Vitafoods European trade show in Geneva next week.

READ: OptiBiotix jumps on news of potential commercial partner SlimBiome and LPLDL nominated for awards

Opti will also present results from its human studies on SlimBiome which showed that people who took the ingredient felt fuller, had less cravings and were more likely or make positive changes to their food choices.

Alongside its manufacturing partner, Sacco, the AIM-listed company will also showcase its LPLDL cholesterol and blood pressure-reducing probiotic in a number of new product concepts, while Opti will also present fresh results of its human studies.

OptiBiotix is also up for a couple of awards at the conference: SlimBiome has been shortlisted for the 'Ingredient of the Year: Weight Management' award, while LPLDL has been shortlisted as 'Probiotic Product of the Year'.

New opportunities

“We are extremely pleased to be attending Vitafoods with a range of new products, new human studies on SlimBiome and a growing list of industry partners,” said chief executive Stephen O’Hara.

“We are confident that our participation at VitaFoods will help progress existing discussions with corporate partners and open up opportunities in new territories for the manufacture and distribution of our growing range of products.”

He added: “Finally, we are really excited by the results of the human study on SlimBiome.”

]]>
Tue, 08 May 2018 07:37:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/196520/optibiotix-to-present-new-products-and-research-data-at-leading-industry-trade-show-next-week-196520.html
<![CDATA[RNS press release - Launch of extended range of products at Vitafoods ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180508070008_13631744/ Tue, 08 May 2018 07:00:08 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180508070008_13631744/ <![CDATA[News - OptiBiotix shares jump amid media interest generated by potential US commercial partner ]]> http://www.proactiveinvestors.co.uk/companies/news/196125/optibiotix-shares-jump-amid-media-interest-generated-by-potential-us-commercial-partner-196125.html OptiBiotix Health plc (LON:OPTI) saw its shares jump on Tuesday after the life science firm noted media interest generated by a potential commercial partner, Seed Health.

In a statement, the AIM-listed firm - which is developing compounds to tackle obesity, high cholesterol, diabetes and skin care - pointed out that Seed has purchased its LP-LD product for use in a multi-strain product intended for launch in the US in May 2018.

READ: OptiBiotix signs agreement with Cambridge Commodities to distribute SlimBiome in the UK

The group noted that an article in Business Insider US refers to clinical studies published in the scientific journal PLOS One showing that one of the probiotics contained in Seed's multi-strain product reduced LDL or "bad" cholesterol and increased HDL or "good" cholesterol.

OptiBiotix reported the results of its human studies using LP-LD in April 2016, and subsequently published them in PLOS in December 2017 and at international conferences, which demonstrated statistical and clinical significant reductions in cholesterol and blood pressure.

The group said the Business Insider article provides a link to OptiBiotix's publication and discloses the use of LP-LDL in Seeds’ product.

OptiBiotix said it can confirm it is in discussions with Seed to agree commercial terms for the use of its LP-LDL strain in Seed's products in preparation for a May launch in the US.

The group added: “Whilst these negotiations are at an advanced stage, they are one of a number of discussions with US partners which may or may not progress to legal agreement. If or when commercial terms are concluded, a further announcement with be made.”

Seed have developed an innovative product concept which combines multiple strains of different probiotics which have been selected because of strong clinical trial data.

International commercial and media interest

Stephen O'Hara, OptiBiotix’s CEO, commented: "We are pleased that the strong science, successful human studies and international awards at major scientific conferences have attracted international commercial and media interest in LP-LDL.”

He added: “This has allowed OptiBiotix to sign manufacturing, formulation/application and distribution partnerships with fast-growing companies with leading market positions in multiple industry sectors across the world.

“We look forward to the opportunity of announcing deals with similar partners in the fast-growing US marker once these have been concluded."

In early trading, OptiBiotix shares were 8.7% higher at 75p.

]]>
Tue, 01 May 2018 08:45:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/196125/optibiotix-shares-jump-amid-media-interest-generated-by-potential-us-commercial-partner-196125.html
<![CDATA[RNS press release - LP-LDL? news media interest in USA ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180501070003_13624744/ Tue, 01 May 2018 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180501070003_13624744/ <![CDATA[RNS press release - Notice of Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180430070018_13622822/ Mon, 30 Apr 2018 07:00:18 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180430070018_13622822/ <![CDATA[Media files - OptiBiotix inks deal with Cambridge Commodities to distribute SlimBiome in UK ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/9142/optibiotix-inks-deal-with-cambridge-commodities-to-distribute-slimbiome-in-uk-9142.html Wed, 25 Apr 2018 12:47:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/9142/optibiotix-inks-deal-with-cambridge-commodities-to-distribute-slimbiome-in-uk-9142.html <![CDATA[News - OptiBiotix signs agreement with Cambridge Commodities to distribute SlimBiome in the UK ]]> http://www.proactiveinvestors.co.uk/companies/news/195626/optibiotix-signs-agreement-with-cambridge-commodities-to-distribute-slimbiome-in-the-uk-195626.html OptiBiotix Health PLC (LON:OPTI) has entered into a non-exclusive agreement for Cambridge Commodities Ltd (CCL) to distribute its SlimBiome weight management technology in the UK.

The AIM-listed firm said the SlimBiome product will be purchased from OptiBiotix and distributed as a specialised branded functional ingredient by CCL - a privately-owned firm which has 10 sales offices covering UK, Europe, USA and South Africa.

WATCH: OptiBiotix inks deal with Cambridge Commodities to distribute SlimBiome in UK

The company said in a statement that the agreement with CCL is complementary to the deal it signed with Knighton Food Ltd on 1 November 2017, as it extends SlimBiome’s commercial reach into new application areas where CCL has specific sector expertise, such as sports, health & wellbeing and ingredients sectors.

Stephen O’Hara, CEO of OptiBiotix, commented: “We believe working with CCL, and similar partners around the world, provides the best opportunity to expand the range of applications for SlimBiome to a wide range of industry sectors.”

He added: “This agreement is another step in our low-cost approach to growing revenues by building manufacturing, formulation/application and distribution partnership which provide revenues across the whole value chain in multiple industry sectors.”

]]>
Tue, 24 Apr 2018 07:32:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/195626/optibiotix-signs-agreement-with-cambridge-commodities-to-distribute-slimbiome-in-the-uk-195626.html
<![CDATA[RNS press release - SlimBiome non-exclusive UK distribution agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180424070002_13615392/ Tue, 24 Apr 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180424070002_13615392/ <![CDATA[News - OptiBiotix appoints new head of online sales and marketing to develop firm’s web presence ]]> http://www.proactiveinvestors.co.uk/companies/news/195337/optibiotix-appoints-new-head-of-online-sales-and-marketing-to-develop-firms-web-presence-195337.html OptiBiotix Health plc (LON:OPTI) has announced the appointment of Steven Riley as head of online sales and marketing from May 2, to develop the company’s web presence.

The AIM-listed firm said Riley - who has over eight years' sales and marketing experience within the food, nutrition and nutraceuticals industries - will lead the development of the OptiBiotix online presence as another revenue generating business in its own right.  

READ: OptiBiotix expands sales into Asia after inking five-year distribution deal with Pakistan pharma

The company said it will use the online platform as a display window to attract potential partners, as they did with GoFigure, which led to a deal with Tata Chemical for its SlimBiome product.

Optibiotix added: "The Company will extend its offering online with the CholBiome range that should enable it to attract further partners for LPLDL such as Trigen Pharma as announced on 18 April 2018."

Per Rehne, Optibiotix's commercial director said: "We want to develop this as display window to attract B2B partners and major retailers. This creates another channel for OptiBiotix that will generate revenues from OptiBiotix’s growing pipeline of products and we believe it has the potential to grow into a business in its own right.”

 

]]>
Thu, 19 Apr 2018 08:03:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/195337/optibiotix-appoints-new-head-of-online-sales-and-marketing-to-develop-firms-web-presence-195337.html
<![CDATA[RNS press release - Appointment of Head of Online Sales and Marketing ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180419070005_13610234/ Thu, 19 Apr 2018 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180419070005_13610234/ <![CDATA[News - OptiBiotix expands sales into Asia after inking five-year distribution deal with Pakistan pharma ]]> http://www.proactiveinvestors.co.uk/companies/news/195223/optibiotix-expands-sales-into-asia-after-inking-five-year-distribution-deal-with-pakistan-pharma-195223.html Life sciences group OptiBiotix Health plc (LON:OPTI) is taking its heart health products into Asia after signing an exclusive five-year distribution agreement with Trigen Pharma.

The deal will see Trigen – one of Pakistan’s leading healthcare groups – promote, distribute and commercialise Opti’s own-label CholBiome products in the South Asian country.

READ: OptiBiotix announces three new patent filings in sweetener market

In return for the exclusivity, Trigen has agreed to cover all costs for product registration with the Drug Regulatory Authority of Pakistan.

The agreement is the first covering the CholBiome range of products and expands Opti’s sales into Asia – a market with huge potential for the company.

In Pakistan alone, cardiovascular disease is responsible for about one-in-five deaths, and more than a third of over-45s suffer from hypertension (high blood pressure).

CholBiome contains OptiBiotix’s LPLDL strain and has been shown to reduce both cholesterol levels and blood pressure.

The AIM-quoted firm said products are difficult to estimate in new markets, but it expects them to be in the low-to-mid six-figures in the near term as Trigen builds market presence.

Strategic step to access Asian market

“We are pleased to announce this agreement with Trigen which expands sales of LPLDL into Pakistan, where high blood pressure and high cholesterol are significant causes of morbidity and mortality,” said chief executive Stephen O’Hara.

“We chose Trigen due to its leading position in Pakistan's pharmaceutical industry, specialism in cardiovascular health, and track record of growing product sales.

“This agreement is a strategic step to access the Asian probiotic market and extend the distribution of OptiBiotix's own label LPLDL formulations like CholBiome into international markets.”

]]>
Wed, 18 Apr 2018 07:41:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/195223/optibiotix-expands-sales-into-asia-after-inking-five-year-distribution-deal-with-pakistan-pharma-195223.html
<![CDATA[RNS press release - CholBiome exclusive distribution agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180418070002_13608389/ Wed, 18 Apr 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180418070002_13608389/ <![CDATA[News - OptiBiotix Health announces three new patent filings in the sweetener market ]]> http://www.proactiveinvestors.co.uk/companies/news/194307/optibiotix-health-announces-three-new-patent-filings-in-the-sweetener-market-194307.html OptiBiotix Health plc (LON:OPTI) has announced three new patent filings to protect the production methods and product application areas arising from its SweetBiotix product development programmes.

The AIM-listed firm said the first patent filing is a natural high-intensity sweetener with improved flavour profile and microbiome modulating functionality.

READ: OptiBiotix Health sweetener performs well in independent taste test

OptiBiotix also announced a patent filing for sweet natural healthy fibres, being developed as potential bulk sugar replacements which are not digested in the human gut, and hence calorie free.

The group said these patent filings follow on from a total of five successful independent human studies in which OptiBiotix's products and comparator samples were tested by an expert panel of 11 panellists who rated 11 products attributes - e.g. sweetness, aftertaste, off- flavour, bitterness etc - compared to sucrose.

The obesity and cholesterol management company said that the global sweetener market, currently dominated by sugar, is forecast to reach US$112bln by 2020. Therefore, the firm believes filing these additional patents will help protect its inventions and fully exploits the commercial opportunities being explored with industry partners.

Stephen O’Hara, OptiBiotix's CEO said: “With growing concerns over traditional sugars and artificial sweeteners, SweetBiotix has the potential to address a global consumer and industry need, addressing international concerns over the impact of sugar an obesity, with the prospect of replacing ‘unhealthy’ sugars in existing products with non-digestible, low calorie, healthy, SweetBiotix.”

]]>
Thu, 05 Apr 2018 07:38:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/194307/optibiotix-health-announces-three-new-patent-filings-in-the-sweetener-market-194307.html
<![CDATA[RNS press release - New patent filings for SweetBiotix ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180405070002_13592283/ Thu, 05 Apr 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180405070002_13592283/ <![CDATA[News - OptiBiotix transitioning to a commercial business, plans to open online store by the end of April ]]> http://www.proactiveinvestors.co.uk/companies/news/193844/optibiotix-transitioning-to-a-commercial-business-plans-to-open-online-store-by-the-end-of-april-193844.html OptiBiotix Health plc (LON:OPTI) has announced that it is gradually transitioning from a research and development company to a commercial business and plans to open its online store by the end of April.

The AIM-listed company said it is building value within each of its three divisions, leveraging the uniqueness of its technology to commercialise food ingredients and products so that each division becomes profitable and self-sustainable.

READ: Optibiotix Health - Microbiome Specialist Entering Commercial Phase

The obesity and cholesterol management company is also building its product portfolio with partners and developing an online store to create a shop window for its technologies and products. It expects this transition to be completed by the end of April. The shop will sell GoFigure products, the wider range of SlimBiome products and LPLDL formulations.

OptiBiotix said it is all part of a gradual transition from a research and development company to a commercial business: “The overall aim is to build revenues within each division to between £5mln-£10mln per annum over the forthcoming years.”

Stephen O’Hara, CEO of OptiBiotix, said: “Industry interest is coming from national retailers and global corporates which have potential for significant upside given the scale of their market reach.”

He added: "We remain on track with our strategy of building multiple revenue streams from both consumer and pharmaceutical products across all our technology platforms."

]]>
Tue, 27 Mar 2018 07:32:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/193844/optibiotix-transitioning-to-a-commercial-business-plans-to-open-online-store-by-the-end-of-april-193844.html
<![CDATA[RNS press release - Scientific and commerical update ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180327070002_13582085/ Tue, 27 Mar 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180327070002_13582085/ <![CDATA[Media files - Optibiotix to launch SlimBiome in Nutri-Bites with US partner ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8855/optibiotix-to-launch-slimbiome-in-nutri-bites-with-us-partner-8855.html Thu, 08 Mar 2018 11:53:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/8855/optibiotix-to-launch-slimbiome-in-nutri-bites-with-us-partner-8855.html <![CDATA[News - OptiBiotix Health says SlimBiome to be used in Cereal Ingredients' Nutri-Bites range of cereal products ]]> http://www.proactiveinvestors.co.uk/companies/news/192820/optibiotix-health-says-slimbiome-to-be-used-in-cereal-ingredients-nutri-bites-range-of-cereal-products-192820.html OptiBiotix Health plc (LON:OPTI) has announced that its SlimBiome weight management technology will be used in US partner Cereal Ingredients' (CII) Nutri-Bites range of cereal products.

The AIM-listed obesity and cholesterol management firm said that the partnership will extend the application of SlimBiome® into products such as breakfast cereals and cookies, cakes as well as a range of healthy snacks, yoghurts, and cereal bars.

READ: OptiBiotix rises as its signs a production and commercialisation agreement

OptiBiotix said the move was a continuation of its focus on the US market following a supply and manufacturing agreement signed with CII in December 2017.

The group added that product range will be showcased at the 2018 Natural Products Expo West & Engredea, the world’s largest trade show for organic, natural and healthy products.

WATCH: Optibiotix to launch SlimBiome in Nutri-Bites with US partner

OptiBiotix's sales and marketing director, Christina Wood, said: “By combining OptiBiotix's award-winning SlimBiome® technology with CII's market-leading ingredients, manufacturing capacity and product development, we have created a delicious functional solution which can help customers manage their weight by reducing snacking and food intake without food cravings.

"We are delighted to share this innovative science-based approach to weight management with food and ingredient buyers from around the world at the Natural Products Expo West & Engredea show."

]]>
Thu, 08 Mar 2018 07:30:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/192820/optibiotix-health-says-slimbiome-to-be-used-in-cereal-ingredients-nutri-bites-range-of-cereal-products-192820.html
<![CDATA[RNS press release - Launch of Slimbiome in Nutri-bites ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180308070007_13559063/ Thu, 08 Mar 2018 07:00:07 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180308070007_13559063/ <![CDATA[News - OptiBiotix rises as its signs a production and commercialisation agreement ]]> http://www.proactiveinvestors.co.uk/companies/news/192660/optibiotix-rises-as-its-signs-a-production-and-commercialisation-agreement-192660.html Shares in OptiBiotix Health plc (LON:OPTI) surged after the human microbiome specialist announced a production and commercialisation agreement with Fine Foods & Pharmaceuticals.

The agreement grants Fine Foods an exclusive licence for the production and supply of five formulations containing OptiBiotix's LPLDL strain in Europe in return for royalty payments and a commitment to maximising the financial return for both parties.

READ: OptiBiotix Health now able to pay dividends following capital reorganisation

LPLDL works by affecting the metabolism of bile acids in the intestine and is a viable non-prescription alternative to cholesterol-lowering statins, which are known to have unwanted side effects for many users.

Fine Foods is based in Italy and has more than 30 years' experience in the design, development and manufacture of customised formulations and presentations for the pharmaceutical and food supplement industry.

It has full good manufacturing practice-certified production facilities and a recognised expertise in developing unique formulations and presentations containing probiotic strains.

Under the terms of the agreement, Fine Foods has an exclusive licence to produce and commercialise five new formulations containing OptiBiotix's LPLDL: one for glucose control; one for reduction of high blood pressure; one for reduction of cholesterol levels and two for the reduction of cardiovascular risk.

These proprietary formulations will be marketed in innovative presentations including sachets and 'melt in the mouth' sticks, to Fine Foods’ extensive European network in both the pharmaceutical and food supplement industry.

“This agreement extends the range of products and presentations containing OptiBiotix's LPLDL and creates an opportunity to access global pharmaceutical markets with an established industry supplier,” said Stephen O’Hara, the chief executive officer of OptiBiotix.

“We chose Fine Foods due to its industry experience, reputation, rapid revenue growth, and impressive client list of global customers in both the pharmaceutical and food supplement sectors. We believe our strategy of identifying and building partnerships with industry-leading partners like Fine Foods, provides the best opportunity of rapidly building revenue streams, and establishing LPLDL as a leading global brand," he added.

House broker finnCap said it was encouraged by the announcement, which continues to demonstrate the company’s ability to attract high calibre, global partners, and eager to use the potential inherent within LPLDL.

“We expect further announcements for regions in which OPTI products can help differentiate and expand existing marketing products,” the broker said.

Shares in OptiBiotix were up 4.7% at 62.8p in early deals. 

]]>
Tue, 06 Mar 2018 08:21:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/192660/optibiotix-rises-as-its-signs-a-production-and-commercialisation-agreement-192660.html
<![CDATA[RNS press release - LPLDL® Exclusive European License Agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180306070002_13555554/ Tue, 06 Mar 2018 07:00:02 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180306070002_13555554/ <![CDATA[News - OptiBiotix Health now able to pay dividends following capital reorganisation ]]> http://www.proactiveinvestors.co.uk/companies/news/192320/optibiotix-health-now-able-to-pay-dividends-following-capital-reorganisation-192320.html Life sciences business OptiBiotix Health plc (LON:OPTI) told shareholders it is now able to make dividend payments in future, should it want to.

The cancellation of its share premium account has been ratified, creating reserves that are available for distribution to shareholders.

"I am pleased to report that both shareholders and the courts have confirmed the capital reduction. This allows OptiBiotix to make future dividend or 'dividend in specie' distributions to the company's shareholders should it be appropriate to do so. This is part of OptiBiotix's strategy of building value across its divisions and where possible releasing value back to shareholders," said Stephen O'Hara, the chief executive officer of OptiBiotix.

]]>
Wed, 28 Feb 2018 07:27:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/192320/optibiotix-health-now-able-to-pay-dividends-following-capital-reorganisation-192320.html
<![CDATA[RNS press release - OptiBiotix Capital Reorganisation ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180228070003_13548256/ Wed, 28 Feb 2018 07:00:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180228070003_13548256/ <![CDATA[RNS press release - Exercise of warrant and issue of equity ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180206070002_13522386/ Tue, 06 Feb 2018 07:00:02 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180206070002_13522386/ <![CDATA[RNS press release - Director's dealing ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180201142216_13518560/ Thu, 01 Feb 2018 14:22:16 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180201142216_13518560/ <![CDATA[Media files - OptiBiotix Health 'in the strongest position they've ever been' ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8691/optibiotix-health-in-the-strongest-position-they-ve-ever-been--8691.html Thu, 01 Feb 2018 12:56:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/8691/optibiotix-health-in-the-strongest-position-they-ve-ever-been--8691.html <![CDATA[RNS press release - Exercise of warrant and issue of equity ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180130150302_13514954/ Tue, 30 Jan 2018 15:03:02 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180130150302_13514954/ <![CDATA[RNS press release - Result of Meeting ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180125114542_13509666/ Thu, 25 Jan 2018 11:45:42 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180125114542_13509666/ <![CDATA[News - OptiBiotix Health sweetener performs well in independent taste test ]]> http://www.proactiveinvestors.co.uk/companies/news/190439/optibiotix-health-sweetener-performs-well-in-independent-taste-test-190439.html An independent study has shown a sweetener developed by OptiBiotix Health PLC (LON:OPTI) scored well against competitors.

The Flavour and Sensory Science Centre at the University of Reading tested eight different samples.

It found the company's oligosaccharides were significantly sweeter than the other products tested, while being low in all “off-flavours” such as bitterness, sourness, staleness and saltiness.

The company is developing sweet, natural, healthy fibres under the SweetBiotix brand, which are not digested in the human gut, and are therefore calorie-free. 

Big potential market 

This would give the research firm entry to the US$100bn a year global sweetener market, which is still dominated by sugar.

OptiBiotix chief executive Stephen O'Hara said he was pleased with the results of the Reading study.

“This development creates the potential to replace existing unhealthy sugars with low calorie, healthy non-digestible fibres (SweetBiotix) with gut microbiome functionality.

“With growing concerns over the impact on health of traditional sugars and artificial sweeteners, the ability to develop sweet functional fibres puts OptiBiotix at the forefront of product development in this area of growing industry and commercial interest."

Human microbiome

The company’s specialism is the human microbiome, an ecosystem of bacteria and yeasts that reside in the gut and on the skin.

It is thought changes to the human flora can have an impact on health, hence the proliferation of functional foods such as yoghurts filled with probiotic, or good bacteria.

OptiBiotix’s focus is mainly on the gut with advances designed to tackle obesity, cholesterol and diabetes although the company does have a separately-quoted business developing skincare products.

In a note to clients, analysts at ‘house’ broker finnCap commented: “This positive taste study further demonstrates the potential for SweetBiotix to replace traditional sugars and artificial sweeteners as a bulk sugar replacement that contains no calories and improves microbiome diversity.”

In late afternoon trading, shares in Optibiotix were 1.6% higher at 635p.

--- Updates share price ---

]]>
Tue, 23 Jan 2018 07:34:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/190439/optibiotix-health-sweetener-performs-well-in-independent-taste-test-190439.html
<![CDATA[RNS press release - SweetBiotix® development: human taste studies ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180123070004_13505357/ Tue, 23 Jan 2018 07:00:04 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180123070004_13505357/ <![CDATA[News - OptiBiotix to showcase industry-leading technology at top conference next month ]]> http://www.proactiveinvestors.co.uk/companies/news/190158/optibiotix-to-showcase-industry-leading-technology-at-top-conference-next-month-190158.html OptiBiotix Health plc’s (LON:OPTI) work on the emerging field of the human microbiome will be recognised at a leading industry conference next month.

For the company is to present an abstract at ProBiota 2018, attended by the movers and shakers of the industry.

READ: Optibiotix Health eyes up future projects

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics which can enhance the growth rate and health benefits of specific microbial species. In doing so they aid the efficacy of probiotic products.

Deeper dive

To understand what this means it is worth going back to first principles. As mentioned, the company’s focus is the human microbiome, an ecosystem of bacteria and yeasts that reside in the gut and on the skin.

It is thought changes to the human flora can have an impact on health, hence the proliferation of functional foods such as yoghurts filled with probiotic, or good bacteria.

OptiBiotix’s focus is mainly on the gut with advances designed to tackle obesity, cholesterol and diabetes although the company does have a separately-quoted business developing skincare products.

What it is showcasing at the ProBiota conference is a prebiotic which helps promote the growth of the health-giving micro-organisms such as Lactobacillus rhamnosus GG, or LGG for short.

This new product concept utilises OptiBiotix's synbiotics technology and has the potential to enhance probiotic health benefits and provide a product that is different to the current me-too offerings.

Designer prebiotics

“The ability to create designer prebiotics which can selectively modulate the growth of an individual species and be used in combination to improve the efficacy of existing probiotics, or by itself to modify an individual's microbiome to improve health, is a hugely exciting development in global microbiome research and product development,” said OptiBiotix chief executive Stephen O’Hara.

“We believe we are fast approaching a future where microbiome products will make a significant contribution to the prevention, management and treatment of disease.

“The ability to create designer ingredients which can precision engineer the microbiome to improve health places OptiBiotix at the forefront of this global health trend."

ProBiota 2018 takes place in Barcelona February 7-9.

]]>
Wed, 17 Jan 2018 08:21:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/190158/optibiotix-to-showcase-industry-leading-technology-at-top-conference-next-month-190158.html
<![CDATA[RNS press release - Presentation of data at European Conference ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180117070003_13498737/ Wed, 17 Jan 2018 07:00:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180117070003_13498737/ <![CDATA[RNS press release - Shareholder Circular and Notice of General Meeting ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180108151203_13488904/ Mon, 08 Jan 2018 15:12:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180108151203_13488904/ <![CDATA[RNS press release - Directorate Changes ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180108070004_13487699/ Mon, 08 Jan 2018 07:00:04 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180108070004_13487699/ <![CDATA[Media files - Optibiotix Health eyes up future projects ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8565/optibiotix-health-eyes-up-future-projects-8565.html Wed, 20 Dec 2017 08:40:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/8565/optibiotix-health-eyes-up-future-projects-8565.html <![CDATA[RNS press release - Exercise of warrant and issue of equity ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171214153518_13466252/ Thu, 14 Dec 2017 15:35:18 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171214153518_13466252/ <![CDATA[News - OptiBiotix inks US manufacturing and supply deal for its SlimBiome appetite suppressant ]]> http://www.proactiveinvestors.co.uk/companies/news/188632/optibiotix-inks-us-manufacturing-and-supply-deal-for-its-slimbiome-appetite-suppressant-188632.html Life sciences group OptiBiotix Health PLC (LON:OPTI) has signed a manufacturing and supply agreement with US-based speciality ingredients manufacturer Cereal Ingredients Inc (CII).

The deal grants CII a licence to manufacture and supply Opti’s SlimBiome appetite suppressant in its range of cereal and protein-based particulates in the USA.

WATCH: Optibiotix Health eyes up future projects

In return, AIM-quoted OptiBiotix will get a 50% cut of the profits, with an agreed cost of manufacture and minimum price already in place.

By partnering with CII, Opti said SlimBiome would now find its way into food products such as cookies, cakes, crackers and cereal bars, as well as cereals.

Under the terms of the agreement, CII will “use their best endeavours” to promote SlimBiome across the USA and bring it to the attention of as many buyers as possible.

READ: Optibiotix Health's Slimbiome wins award at major food event

Opti called Tuesday’s tie-up a “strategic step” in its bid to access the global healthy ingredients markets, which is estimated will be worth US$101bn by 2022.

“We chose Cereal Ingredients due to their industry reputation and world leading expertise in incorporating functional ingredients like SlimBiome into extruded cereal and protein based particulates bringing added value and differentiation to the cereal, snacks and sports nutrition markets,” said Opti chief executive Stephen O’Hara.

READ: Coffee that loses you weight among products being developed by Optibiotix

“We were particularly impressed by the investment in development work, marketing and customer engagement carried out by CII during negotiations which have given both companies a high level of confidence in the scale of the opportunity open to us.

“We believe working with CII, and similar partners around the world, provides the best opportunity of fully exploiting the functional benefits of SlimBiome to improve the health of customers around the world.”

]]>
Tue, 12 Dec 2017 07:36:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/188632/optibiotix-inks-us-manufacturing-and-supply-deal-for-its-slimbiome-appetite-suppressant-188632.html
<![CDATA[RNS press release - Manufacturing, supply & profit sharing agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171212070002_13461541/ Tue, 12 Dec 2017 07:00:02 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171212070002_13461541/ <![CDATA[News - Lower blood pressure guidance will highlight Optibiotix's cholesterol reducer believes chief ]]> http://www.proactiveinvestors.co.uk/companies/news/188464/lower-blood-pressure-guidance-will-highlight-optibiotix-s-cholesterol-reducer-believes-chief-188464.html A reduction in levels of blood pressure required for a diagnosis of hypertension will highlight the advantages of non-prescription alternatives, believes Stephen O’Hara at Optibiotix Health PLC (LON:OPTI) .

Last month the American Heart Association changed its classification of high blood pressure to a reading of 130/80 from 140/90, a move that instantly put half of the US population in the unhealthy category.

Reports in the UK have suggested that health watchdog NICE (National Institute for Health and Care Excellence) is also considering lower guidance, action that would classify millions more Britons as medically unfit.

“There is no natural cut-off point above which ‘hypertension’ definitively exists and below which it does not” NICE said.

High blood pressure, or hypertension, hardens the arteries and increases the risk of heart disease, diabetes and strokes

Heart problems account for a quarter of all deaths in the UK.

O’Hara, Optiobiotix’s chief executive, believes a new class of probiotics that modulate the human microbiome can help people with high blood pressure to manage the condition.

Statins are the standard treatment to lower cholesterol but O'Hara says LPldl is a viable non-prescription alternative.

“We believe that our microbiome modulating probiotic, LPLDL, is not only a cutting-edge scientific development, but a safe and natural way for people to reduce their blood pressure, and to effectively manage their long-term cardiovascular risk,” he said in an article in Nutraceutical Review.

A study at Reading University showed it was a safe and reduced LDL cholesterol by up to 13.9%, and blood pressure by 5.1%.

LPldl works by affecting the metabolism of bile acids in the intestine and was chosen after 4,000 microbial candidates were assessed using Optibiotix’s Optiscreen platform.

]]>
Thu, 07 Dec 2017 14:28:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/188464/lower-blood-pressure-guidance-will-highlight-optibiotix-s-cholesterol-reducer-believes-chief-188464.html
<![CDATA[Media files - Cheers for the new Chairman at Optibiotix ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8493/cheers-for-the-new-chairman-at-optibiotix-8493.html Tue, 05 Dec 2017 15:55:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/8493/cheers-for-the-new-chairman-at-optibiotix-8493.html <![CDATA[News - OptiBiotix names food industry heavy hitter as its new chairman ]]> http://www.proactiveinvestors.co.uk/companies/news/188242/optibiotix-names-food-industry-heavy-hitter-as-its-new-chairman-188242.html Life sciences group OptiBiotix Health plc (LON:OPTI) is recruiting a food industry heavy hitter to the role of chairman.

Former Express Dairies and Arla Foods chief executive Neil Davidson will take over from Adam Reynolds next month.

Currently a non-executive with the supermarket giant Wm Morrison (LON:MRW), he has also been an independent director at the housebuilder Persimmon (LON:PSN).

It means the new boardroom hire brings with him significant FTSE 100 experience – although he also chaired AIM-quoted Produce Investments.

Personal interest in innovation 

OptiBiotix said Davidson “has a personal interest in the development and commercialisation of technology to improve health”. 

That would appear to make him the ideal fit with the Opti, a pioneer of the human microbiome found in the gut.

It is using its knowledge and discoveries to develop healthy sweeteners and natural alternatives to current drugs for cholesterol and diabetes.

Chief executive Stephen O’Hara said of the chairman-elect: “His network of contacts and wealth of experience on the board of some of the UK's largest public companies will help guide OptiBiotix as it builds a microbiome business in what is forecast to be one of the world's fastest growth areas.

“The board anticipates a future where microbiome products will be at the forefront of preventing, managing and treating many of today's chronic lifestyle disease and we hope under Neil's guidance OptiBiotix will continue to be one of the world's leaders in this exciting and emerging field.”

The shares rose 3% in morning trade to 69.37p, valuing the business at £52mln.

---adds share price---

]]>
Tue, 05 Dec 2017 07:29:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/188242/optibiotix-names-food-industry-heavy-hitter-as-its-new-chairman-188242.html
<![CDATA[RNS press release - Proposed directorate changes ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171205070010_13453703/ Tue, 05 Dec 2017 07:00:10 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171205070010_13453703/